✦ LIBER ✦

A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma

✍ Scribed by Marie Von Lilienfeld-Toal; Corinna Hahn-Ast; Kerstin Furkert; Florian Hoffmann; Ralph Naumann; Ralf Bargou; Gordon Cook; Axel Glasmacher

Book ID: 114794450
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 204 KB
Volume: 81
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2008.01121.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A systematic review of phase-II trials o

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

✍ Axel Glasmacher; Corinna Hahn; Florian Hoffmann; Ralph Naumann; Hartmut Goldschm 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

Phase II trial of temsirolimus in patien

Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma

✍ Sherif S. Farag; Shuhong Zhang; Buffy S. Jansak; Xiaojing Wang; Eric Kraut; Kenn 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 508 KB

In a phase II trial, 16 patients with relapsed refractory multiple myeloma received temsirolimus 25mg I.V. weekly until progression. One partial response and 5 minor responses were observed for a total response rate of 38%. The median time to progression was 138 days. Grade 3-4 toxicity included fat

Phase II and pharmacokinetic study of th

Phase II and pharmacokinetic study of thalidomide in Japanese patients with relapsed/refractory multiple myeloma

✍ Hirokazu Murakami; Kazuyuki Shimizu; Morio Sawamura; Kenshi Suzuki; Isamu Sugiur 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 207 KB

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB

Efficacy of single-agent bortezomib vs.

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison

✍ H. Miles Prince; Michael Adena; Dell Kingsford Smith; Judy Hertel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 593 KB